Track bills, resolutions, and amendments moving through Congress
ENFORCE Act
The bill strengthens federal tools to prosecute and limit circulation of obscene child sexual imagery and to monitor offenders—improving protections for children and public safety—but it expands federal reach and enforcement powers in ways that raise pretrial liberty, fair-trial, reintegration, coordination, and fiscal concerns.
Scam Compound Accountability and Mobilization Act
The bill strengthens U.S. tools, coordination, and victim support to disrupt offshore scam compounds and recover funds, but does so at the cost of heightened diplomatic friction, privacy and due‑process risks, increased public and private-sector costs, and uncertainty from time-limited authorities.
SUPPORT for Patients and Communities Reauthorization Act of 2025
The bill directs substantial new funding and program changes to expand prevention, treatment, and support for substance use and behavioral health—potentially improving access and capacity—while increasing federal spending, administrative requirements, and some legal/privacy risks that could complicate implementation and unevenly affect access across states.
Stop Chinese Fentanyl Act of 2025
The bill aims to disrupt fentanyl supply chains and increase oversight and legal certainty for trade, but it does so at the cost of reduced rapid‑response flexibility, potential economic and supply‑chain harms, and risks of overbroad sanctions that could hurt lawful actors.
HALT Fentanyl Act
To direct the Commandant of the Coast Guard to update the policy of the Coast Guard regarding the use of medication to treat drug overdose, and for other purposes.
The bill improves maritime safety and Coast Guard readiness by clarifying onboard drug offenses and expanding naloxone access and oversight, but it risks narrowing prosecutorial reach, adding costs, raising privacy concerns, and leaving some units with inadequate naloxone access.
SHIELD Against CCP Act
The bill centralizes and clarifies federal coordination, transparency, and technology efforts to address CCP-related threats—strengthening preparedness and interagency response—while increasing costs, information-sharing, and risks to privacy and potentially targeted communities.
HALT Fentanyl Act
The bill tightens and expedites federal control and prosecution of fentanyl analogues to deter trafficking and speed enforcement, while attempting to facilitate regulated research and clarify law — but it raises substantial risks to research access, civil liberties, business and enforcement costs, and oversight that may shift harms or create legal uncertainty.
Expressing support for the designation of February 23, 2025, to March 1, 2025, as "National Fentanyl Awareness Week" and raising awareness of the negative impacts of fentanyl in the United States.
The resolution raises important public- and policymaker awareness about the severe risks of fentanyl and supports calls for action, but as a findings-only text it provides no direct services and risks increasing stigma or shifting attention toward border-focused responses rather than expanding domestic treatment and harm-reduction.
Condemning the pardon of ex-Honduran President Juan Orlando Hernandez.
The resolution exposes large-scale cocaine flows and foreign corruption to justify stronger U.S. counternarcotics and assistance efforts, but doing so risks diplomatic friction, politicization, and weakening cooperation with Honduran security partners that U.S. efforts rely on.
Supporting the goals and ideals of Red Ribbon Week during the period of October 23 through October 31, 2025.
The resolution boosts national awareness and promotes safer medication disposal—helpful for prevention—but relies on symbolic activities and law-enforcement framing that risk diverting attention, funds, and public-health focus away from evidence-based treatment and harm reduction.
Supporting the designation of October 2025 as "Substance Use & Misuse Prevention Month" to raise awareness of substance use and misuse in the United States.
The resolution raises awareness and provides data that can support prevention and treatment expansion, especially for youth, but it is non-binding and risks raising expectations or stigmatizing people who use drugs unless followed by funded, evidence-based policy actions.
Designating August 21, 2025, as "Fentanyl Prevention and Awareness Day".
The bill creates an annual national observance to raise awareness, coordinate outreach, and recognize affected families, but it does so without new funding and could shift emphasis away from evidence-based harm-reduction services.
Commending Federal, State, and local law enforcement for their efforts in protecting Americans by combating drug trafficking and agroterrorism and for their recent actions in Kansas and across the country.
The resolution highlights and supports interdiction and biosecurity successes that can protect public health and agriculture and justify continued enforcement resources, but its alarmist framing risks civil‑liberty tradeoffs, stigmatizing immigrants, and could be used to prioritize costly enforcement over treatment and prevention.
Designating June 6, 2025, as National Naloxone Awareness Day.
The resolution raises awareness about naloxone and could save lives by encouraging bystander and professional use, but it provides no funding and risks diverting attention from prevention and treatment needs.
Supporting the mission and goals of National Fentanyl Awareness Day in 2025, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.
The resolution strengthens awareness, public-health prioritization, and law‑enforcement justification against counterfeit fentanyl—potentially reducing youth harm—but leans toward enforcement-driven responses that may increase policing, taxpayer costs, and pressure on online speech.
To direct the removal of United States Armed Forces from hostilities that have not been authorized by Congress.
The resolution strengthens Congressional control, transparency, and legal limits on presidential use of force—reducing risks of unilateral or unauthorized military action—while making it harder for the Executive to act quickly against emerging threats and possibly increasing political, operational, and fiscal burdens.
MATE Improvement Act
The bill clarifies and retroactively affirms podiatrists' federal authority to register for and prescribe controlled substances—improving access and legal protection for patient care—while modestly increasing diversion risk and imposing reconciliation burdens on regulators and registrants.
Joint Task Force to Counter Illicit Synthetic Narcotics Act of 2025
The bill centralizes and strengthens federal coordination, leadership, and operational capacity to disrupt synthetic‑opioid supply chains and improve information‑sharing—potentially reducing overdoses—but does so with higher federal costs, greater federal control over local responses, civil‑liberties and privacy risks, and possible diplomatic consequences.
Bipartisan Health Care Act
This bill boosts transparency, expands public‑health preparedness and targeted health program funding, and strengthens beneficiary protections—while imposing substantial new federal spending, widespread reporting and compliance costs, privacy and procedural tradeoffs, and implementation uncertainty that could shift costs to states, providers, employers, and patients.
BUST FENTANYL Act
HIDTA Enhancement Act
The bill directs significant, targeted federal funding and staffing to strengthen fentanyl interdiction and prosecution and improves HIDTA reporting, trading taxpayer cost, potential diversion of prosecutorial focus, and civil liberties/data-sharing risks for increased law-enforcement capacity and transparency.
Temporary Extension of Fentanyl-Related Substances Scheduling Act
The bill extends temporary control over fentanyl-related substances for six months, preserving law-enforcement and public-health tools to address rapidly evolving analogues but at the cost of continued criminal penalties for some individuals, delayed regulatory clarity for researchers and suppliers, and additional enforcement expenses.
CATCH Fentanyl Act
The bill aims to accelerate testing and adoption of AI and advanced sensing at land ports to improve detection and throughput and increase transparency, but it does so within existing budget limits—raising fiscal, privacy, safety, and procurement-shaping risks that could undercut intended benefits or shift costs elsewhere.
Overdose RADAR Act
The bill would improve overdose detection, harm reduction, and federal coordination—potentially expanding prevention and treatment access—but increases data-sharing and regulatory reach while leaving funding, privacy protections, and implementation burdens uncertain.
Alan T. Shao II Fentanyl Public Health Emergency and Overdose Prevention Act
The bill aims to reduce fentanyl inflow and speed immigration removals by centralizing authority and enabling temporary entry restrictions—potentially improving border safety and administrative speed but risking reduced treatment investment, greater policing and stigma for people who use drugs, and serious restrictions on immigrants' rights and due process.
OPIOIDS Act
The bill strengthens overdose surveillance, forensic capacity, and interagency data sharing to better detect and investigate fentanyl-related threats, but it relies on voluntary standards and lacks guaranteed funding while raising significant privacy and administrative-burden concerns.
Caribbean Border Counternarcotics Strategy Act
The bill strengthens federal coordination and tools to disrupt Caribbean drug trafficking and protect commerce, but does so at the cost of potential privacy intrusions, fiscal and local-capacity burdens, and added friction for legitimate trade and travel.
Combating Illicit Xylazine Act
The bill standardizes and tightens federal control over xylazine—improving enforcement clarity and public-health data—but does so at the cost of higher compliance burdens, possible reduced access to legitimate veterinary/medical uses, and expanded criminal penalties that may worsen disparities and divert focus from treatment.
Pharmacy Benefit Manager Transparency Act of 2025
The bill increases PBM transparency, regulatory enforcement, and whistleblower protections to curb abusive PBM practices and help pharmacies and patients, but it also raises compliance, enforcement, and litigation costs and creates regulatory and privacy uncertainties that could be passed on to consumers and complicate operations for businesses and government programs.
